home.aspx
 
. https://pharmaceutical.report/Resources/Whitepapers/315e66ee-4712-4781-bbe6-d23c67ad1d62_clinical-breakthroughs-in-urological-cancers.pdf
whitepaper
SHARESHARESHARE
CLINICAL BREAKTHROUGHS IN UROLOGICAL CANCERS CAN BE A DOUBLE-EDGED SWORD AS PAYERS ARE FORCED TO ACT
Checkpoint inhibitors in bladder cancer, combination regimens in renal cell carcinoma (RCC) and novel anti-androgens in early prostate cancer treatment lines have demonstrated patient benefit, increasing survival times and addressing major areas of unmet need. However, payers are concerned about the potential impact of these therapies due to their high costs and sometimes extended treatment durations. DOWNLOAD